Genmab – Talk Bio

Genmab Discontinues ProfoundBio-Derived ADC GEN1107 After Acquisition, Paralleling J&J’s Ambrx Buyout Area Developments

3 weeks ago talkbio0Tagged AbbVie, Acquisition, Ambrx, Antibody-Drug Conjugates, Drug Development, GEN1107, Genmab, J&J, Johnson and Johnson, Neoplasms, ProfoundBio, PTK7, PTK7 protein, human

Genmab; ProfoundBio; antibody-drug conjugate (ADC); GEN1107; PTK7; Ambrx; Johnson & Johnson (J&J); oncology; drug development; biotech acquisition; AbbVie lawsuit

Genmab CEO on the $8B Acquisition of Merus: Strategy Behind the ‘Very Fair’ Deal and Plans to Polish a Rough Diamond

2 months ago talkbio0Tagged Acquisition, Antibodies, Bispecific, Breakthrough Therapy, Cancer of Neck, CEO, expansion, Genmab, Head, Merus, Neoplasms, Perspective, Petosemtamab, pipeline, United States Food and Drug Administration

Genmab; Merus; petosemtamab; acquisition; oncology; head and neck cancer; bispecific antibody; FDA Breakthrough Therapy; pipeline expansion; biotech; $8B deal; CEO perspective

Genmab Abandons ADC Asset Acquired in $1.8B ProfoundBio Deal

3 months ago talkbio0Tagged Acquisition, ADC, Antibody-Drug Conjugates, Genmab, Neoplasms, ProfoundBio, therapeutic autologous dendritic cells

Genmab; ProfoundBio; antibody-drug conjugates; ADC; acquisition; oncology; Rina-S

AbbVie and Genmab Move to Expand Use of T Cell Engager Epkinly Following Strong Phase III Results

4 months ago talkbio0Tagged AbbVie, Antibodies, Bispecific, Approved, Epcoritamab, EPKINLY, expansion, Genmab, Labels (device), lenalidomide, Lymphoma, Follicular, Phase 3 Clinical Trials, rituximab, T-Cell engager, United States Food and Drug Administration

Epkinly; epcoritamab; AbbVie; Genmab; follicular lymphoma; T cell engager; bispecific antibody; Phase III trial; FDA approval; label expansion; Rituximab; Lenalidomide

Genmab Exercises Option for Second Commercial License Agreement with Scancell Holdings

1 year ago talkbio0Tagged Cancer Therapeutic Procedure, Genmab, GlyMab platform, Immunotherapy, licensing agreement, Monoclonal Antibodies, Scancell Holdings

Genmab, Scancell Holdings, monoclonal antibody, GlyMab platform, licensing agreement, cancer treatment, immunotherapies

Genmab Streamlines Portfolio by Cutting Early-Stage Oncology Assets

1 year ago talkbio0Tagged Early-stage, Genmab, Neoplasms, Optimization, Phase, portfolio

Genmab, oncology, early-stage candidates, portfolio optimization, Phase 3 projects

Genmab Streamlines Operations by Cutting 3 Early-Stage Programs to Boost Phase 3 Pipeline

1 year ago talkbio0Tagged clinical programs, Genmab, Strategic Focus

Genmab, biotech, clinical programs, phase 3 pipeline, strategic focus

FDA Approval Milestones: X4 Pharmaceuticals, Pfizer, and Genmab Secure Nods for Rare Disease and Cervical Cancer Treatments

2 years ago talkbio0Tagged Biotechnology, Drug Approval, Genmab, Health care facility, Malignant tumor of cervix, Pfizer, United States Food and Drug Administration

FDA, X4 Pharmaceuticals, Pfizer, Genmab, rare disease, cervical cancer, drug approval, treatment, healthcare, biotechnology.

Genmab Acquires ProfoundBio for $1.8 Billion to Challenge AbbVie’s Elahere in ADC Market

2 years ago talkbio0Tagged AbbVie's, Acquisition (action), Antibody-Drug Conjugates, competition, Elahere, FOLR1 gene, FOLR1 protein, human, Genmab, Midphase clinical trials, ProfoundBio, Rina-S, Rinatabart sesutecan

Genmab, ProfoundBio, $1.8 billion acquisition, Antibody Drug Conjugates (ADCs), Competition with AbbVie’s Elahere, Rinatabart sesutecan (Rina-S), Folate Receptor Alpha (FRα), Midphase clinical trials